Pregabalin Capsule
Product Images NDC 60760-682

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

682-30 (Pregabalin 60760 682 30)

Pregabalin Capsules 150 mg packaging label showing a quantity of 30 capsules. The label includes the product NDC 60760-682-30, manufacturer information as Alkem Laboratories Ltd., Mumbai, India, and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, Arizona. The label also features a barcode, lot number and expiration date placeholders, and a statement to use as directed.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A text image showing a formula for creatinine clearance (CLCr) calculation. It includes variables for age (years), weight (kg), serum creatinine (mg/dL), and a factor multiplier of 0.85 for female patients.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

A bar graph showing responder rates (%) on the y-axis and treatment groups on the x-axis. The groups compared are Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The graph includes sample sizes for each group below the x-axis. Responder rates increase from placebo to the highest dose.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

Bar chart displaying responder rates (%) in two studies (E1 and E3) for Pregabalin at various dosages compared to placebo. Study E1 shows increasing responder rates with doses from 50 mg/day to 600 mg/day given BID, with the highest rate at 51%. Study E3 compares placebo, 600 mg/day BID, and 600 mg/day TID, with rates from 9% to 49%. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day). The graph shows results from multiple studies (E1 BID, E2 TID, E3 BID, E3 TID) with different dose levels up to 600 mg/day, illustrating significant seizure reduction at various doses compared to placebo. Key p-values denoting statistical significance are included.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared with placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows percent of patients improved.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line chart showing the percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF. The chart compares two groups labeled as Pregabalin and Placebo, with the Pregabalin group's values represented by a solid line and the Placebo group's by a dotted line, illustrating a higher percentage of improvement in the Pregabalin group across the measured values.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line chart showing the percent of subjects improved over time from baseline to Week 16, comparing Pregabalin and placebo groups. The x-axis represents the percent improvement range, and the y-axis shows the percent of subjects improved, with Pregabalin depicted by a solid line and placebo by a dashed line.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph depicting the percent of patients showing improvement versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day to placebo, showing a higher percent of patients improved with Pregabalin across various levels of pain improvement.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day compared to placebo. The graph shows a descending trend in patient improvement as pain improvement increases.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph comparing the percent of patients improved by the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows a declining trend of patient improvement as pain improvement percentages increase from 0 to 100.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph illustrates the efficacy differences among these treatments over a pain improvement scale from 0 to 100 percent.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. It compares the effects of Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg against placebo, showing trends of patient improvement with increasing dose levels.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A line graph comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The vertical axis represents percent subjects without LTR, and the horizontal axis represents days. The Pregabalin group shows a higher percentage of subjects without LTR throughout the timeline compared to placebo.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin, illustrating its molecular composition including an amino group and a carboxylic acid group attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.